Astellas and Vir Biotechnology Enter Global Strategic Collaboration to Advance Prostate Cancer Treatment VIR-5500
This collaboration combines Astellas' oncology expertise and commercial reach with Vir's innovative PRO-XTEN platform, potentially accelerating the delivery of a new class of T-cell engager therapy for prostate cancer.
安斯泰来与Vir Biotechnology达成全球战略合作，共同开发和商业化用于治疗前列腺癌的新型T细胞衔合器VIR-5500，Vir将获得3.35亿美元的初始付款。
Astellas Pharma and Vir Biotechnology have initiated a global strategic collaboration to co-develop and co-commercialize VIR-5500, a novel T-cell engager for treating prostate cancer. Vir Biotechnology will receive $335 million in initial payments. The partnership will share development costs, with Astellas leading future development and global commercialization. Vir Biotechnology retains co-promotion rights in the United States. This collaboration aims to accelerate the development of VIR-5500, which is currently in Phase I trials.
This collaboration combines Astellas' oncology expertise and commercial reach with Vir's innovative PRO-XTEN platform, potentially accelerating the delivery of a new class of T-cell engager therapy for prostate cancer. The deal structure allows both companies to share risk and reward, creating a strong incentive to advance VIR-5500 through clinical trials and into the market, addressing a significant unmet need in advanced prostate cancer treatment.
此信号在行业全局中的位置。
暂无近期信号追踪。
https://www.prnewswire.com/news-releases/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer-302694866.html
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录